Blister Pack - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Blister Pack

The Experts below are selected from a list of 2166 Experts worldwide ranked by ideXlab platform

Catherine Goodman – One of the best experts on this subject based on the ideXlab platform.

  • IMPACT2 patient adherence to Artemether-Lumefantrine: Smart Blister Pack time stamp data
    , 2017
    Co-Authors: Catherine Goodman, Katia Bruxvoort, Eleanor Challenger


    Dataset containing details of the intended number of Artemether-lumefantrine (AL) treatments given to 482 Tanzanian patients. Variables include the number of doses appropriate to each person, start time when the Blister Pack was first opened, and the relative time that doses 1-23 were subsequently allocated, relative to the start time. Data were captured using smart Blister Packs of artemether-lumefantrine (AL). These Blister Packs looked identical to locally available AL (Coartem) but contained a microchip that recorded a time stamp when each tablet of AL was removed from the Blister Pack.

  • Measuring Patient Adherence to Malaria Treatment: A Comparison of Results from Self-Report and a Customised Electronic Monitoring Device
    PLOS ONE, 2015
    Co-Authors: Katia Bruxvoort, Charles Festo, Matthew Cairns, Admirabilis Kalolella, Frank Mayaya, David Schellenberg, S. Patrick Kachur, Catherine Goodman


    Self-report is the most common and feasible method for assessing patient adherence to medication, but can be prone to recall bias and social desirability bias. Most studies assessing adherence to artemisinin-based combination therapies (ACTs) have relied on self-report. In this study, we use a novel customised electronic monitoring device-termed smart Blister Packs-to examine the validity of self-reported adherence to artemether-lumefantrine (AL) in southern Tanzania. Smart Blister Packs were designed to look identical to locally available AL Blister Packs and to record the date and time each tablet was removed from Packaging. Patients obtaining AL at randomly selected health facilities and drug stores were followed up at home three days later and interviewed about each dose of AL taken. Blister Packs were requested for pill count and extraction of smart Blister Pack data. Data on adherence from both self-report verified by pill count and smart Blister Packs were available for 696 of 1,204 patients. There was no difference between methods in the proportion of patients assessed to have completed treatment (64% and 67%, respectively). However, the percentage taking the correct number of pills for each dose at the correct times (timely completion) was higher by self-report than smart Blister Packs (37% vs. 24%; p

  • Picture of a smart Blister Pack showing resemblance to regular Blister Packs.
    , 2015
    Co-Authors: Katia Bruxvoort, Charles Festo, Matthew Cairns, Admirabilis Kalolella, Frank Mayaya, Patrick S. Kachur, David Schellenberg, Catherine Goodman


    Picture of a smart Blister Pack showing resemblance to regular Blister Packs.

Paul Hugo M. Van Der Kuy – One of the best experts on this subject based on the ideXlab platform.

  • Determining the feasibility of objective adherence measurement with Blister Packaging smart technology
    American Journal of Health-System Pharmacy, 2012
    Co-Authors: Hein A. Van Onzenoort, Cees Neef, Willem W. Verberk, H. Peter Van Iperen, Peter W De Leeuw, Paul Hugo M. Van Der Kuy


    PURPOSE: The results of a feasibility study of BlisterPack smart technology for monitoring medication adherence are reported.\n\nMETHODS: Research in the area of objective therapy compliance measurement has led to the development of microprocessor-driven systems that record the time a unit dose is removed from Blister Packaging. One device under development is the Smart Blister-a label imprinted with event-detection circuitry that can be affixed to standard commercial Blister cards. In the first trial of the device in actual clinical practice, 115 community-dwelling Dutch patients receiving valsartan maintenance therapy (160 mg once daily) were given 14-day Blister Packages equipped with the Smart Blister. On the return of empty Blister cards to the 20 participating community pharmacies, the stored information was scanned and downloaded for data analysis and patient counseling purposes.\n\nRESULTS: A total of 245 Smart Blister-equipped Packages were used by valsartan recipients during the eight-month study. The device was largely effective in recording patient and Blister-card identification data and other desired information. However, in 17% of cases, the Smart Blister system registered multiple tablet-removal events at the same time, presumably indicating unintentional breakage of nearby conductive circuits and the need for design refinements. The Smart Blister-equipped medication cards were generally well received by patients and pharmacies.\n\nCONCLUSION: An evaluation of the functionality and robustness of the Smart Blister in a real-world clinical practice situation yielded some promising results, but the findings also indicated a need for design refinements and additional performance testing of the device.

Margaret Hellard – One of the best experts on this subject based on the ideXlab platform.

  • adherence to sofosbuvir and velpatasvir among people with chronic hcv infection and recent injection drug use the simplify study
    International Journal of Drug Policy, 2018
    Co-Authors: Evan B Cunningham, Margaret Hellard, Janaki Amin, Jordan J Feld, Julie Bruneau, Olav Dalgard, Jeff Powis


    Abstract Background This study investigated treatment adherence among people with recent injecting drug use in a study of sofosbuvir/velpatasvir therapy for HCV infection. Methods SIMPLIFY is an international open-label, single-arm multicentre study that recruited participants with recent injecting drug use (previous six months) and chronic HCV genotype (G) 1–6 infection between March and October 2016 in seven countries (19 sites). Participants received sofosbuvir/velpatasvir once-daily for 12 weeks administered in a one-week electronic Blister Pack (records the time and date of each dose) for 12 weeks. We evaluated non-adherence ( Results Among 103 participants, 97% (n = 100) completed treatment. Median adherence to therapy was 94%. Overall, 32% (n = 33) were considered non-adherent ( Conclusion This study demonstrated high adherence to once-daily sofosbuvir/velpatasvir therapy among a population of people with recent injecting drug use. Recent stimulant injecting prior to and during DAA therapy and inconsistent dose-timing during treatment was associated with non-adherence. However, there was no impact of non-adherence on response to therapy, suggesting that adherence is not a significant barrier to successful DAA therapy in people with recent injecting drug use.